2018-2023 Global Checkpoint Inhibitors for Treating Cancer Consumption Market Report
- LP 2647883
- 130 Pages
- July 2018
- Pharmaceuticals
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.
Over the next five years, LPI(LP Information) projects that Checkpoint Inhibitors for Treating Cancer will register a 28.0% CAGR in terms of revenue, reach US$ 20600 million by 2023, from US$ 4690 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Checkpoint Inhibitors for Treating Cancer market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segmentation by application:
Melanoma Treatment
Bladder Cancer Treatment
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Bristol-Myers Squibb(BMS)
Merck
Roche
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Checkpoint Inhibitors for Treating Cancer consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Checkpoint Inhibitors for Treating Cancer market by identifying its various subsegments.
Focuses on the key global Checkpoint Inhibitors for Treating Cancer manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Checkpoint Inhibitors for Treating Cancer with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Checkpoint Inhibitors for Treating Cancer submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
2018-2023 Global Checkpoint Inhibitors for Treating Cancer Consumption Market Report
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Consumption 2013-2023
2.1.2 Checkpoint Inhibitors for Treating Cancer Consumption CAGR by Region
2.2 Checkpoint Inhibitors for Treating Cancer Segment by Type
2.2.1 PD-1 Inhibitors
2.2.2 PD-L1 Inhibitors
2.2.3 CTLA-4 Inhibitors
2.3 Checkpoint Inhibitors for Treating Cancer Consumption by Type
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2013-2018)
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2013-2018)
2.3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Type (2013-2018)
2.4 Checkpoint Inhibitors for Treating Cancer Segment by Application
2.4.1 Melanoma Treatment
2.4.2 Bladder Cancer Treatment
2.4.3 Other
2.5 Checkpoint Inhibitors for Treating Cancer Consumption by Application
2.5.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2013-2018)
2.5.2 Global Checkpoint Inhibitors for Treating Cancer Value and Market Share by Application (2013-2018)
2.5.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2013-2018)
3 Global Checkpoint Inhibitors for Treating Cancer by Players
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Players
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Players (2016-2018)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Players (2016-2018)
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Players
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Players (2016-2018)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Players (2016-2018)
3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Players
3.4 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Checkpoint Inhibitors for Treating Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Checkpoint Inhibitors for Treating Cancer by Regions
4.1 Checkpoint Inhibitors for Treating Cancer by Regions
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Consumption by Regions
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Value by Regions
4.2 Americas Checkpoint Inhibitors for Treating Cancer Consumption Growth
4.3 APAC Checkpoint Inhibitors for Treating Cancer Consumption Growth
4.4 Europe Checkpoint Inhibitors for Treating Cancer Consumption Growth
4.5 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Growth
5 Americas
5.1 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Countries
5.1.1 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018)
5.1.2 Americas Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018)
5.2 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Type
5.3 Americas Checkpoint Inhibitors for Treating Cancer Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Countries
6.1.1 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018)
6.1.2 APAC Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018)
6.2 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Type
6.3 APAC Checkpoint Inhibitors for Treating Cancer Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Checkpoint Inhibitors for Treating Cancer by Countries
7.1.1 Europe Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018)
7.1.2 Europe Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018)
7.2 Europe Checkpoint Inhibitors for Treating Cancer Consumption by Type
7.3 Europe Checkpoint Inhibitors for Treating Cancer Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer by Countries
8.1.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018)
8.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Type
8.3 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Checkpoint Inhibitors for Treating Cancer Distributors
10.3 Checkpoint Inhibitors for Treating Cancer Customer
11 Global Checkpoint Inhibitors for Treating Cancer Market Forecast
11.1 Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast (2018-2023)
11.2 Global Checkpoint Inhibitors for Treating Cancer Forecast by Regions
11.2.1 Global Checkpoint Inhibitors for Treating Cancer Forecast by Regions (2018-2023)
11.2.2 Global Checkpoint Inhibitors for Treating Cancer Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Checkpoint Inhibitors for Treating Cancer Forecast by Type
11.8 Global Checkpoint Inhibitors for Treating Cancer Forecast by Application
12 Key Players Analysis
12.1 Bristol-Myers Squibb(BMS)
12.1.1 Company Details
12.1.2 Checkpoint Inhibitors for Treating Cancer Product Offered
12.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Bristol-Myers Squibb(BMS) News
12.2 Merck
12.2.1 Company Details
12.2.2 Checkpoint Inhibitors for Treating Cancer Product Offered
12.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Merck News
12.3 Roche
12.3.1 Company Details
12.3.2 Checkpoint Inhibitors for Treating Cancer Product Offered
12.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 Roche News
...
13 Research Findings and Conclusion
Figure Picture of Checkpoint Inhibitors for Treating Cancer
Table Product Specifications of Checkpoint Inhibitors for Treating Cancer
Figure Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure Market Research Methodology
Figure Global Checkpoint Inhibitors for Treating Cancer Consumption Growth Rate 2013-2023 (g)
Figure Global Checkpoint Inhibitors for Treating Cancer Value Growth Rate 2013-2023 ($ Millions)
Table Checkpoint Inhibitors for Treating Cancer Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of PD-1 Inhibitors
Table Major Players of PD-1 Inhibitors
Figure Product Picture of PD-L1 Inhibitors
Table Major Players of PD-L1 Inhibitors
Figure Product Picture of CTLA-4 Inhibitors
Table Major Players of CTLA-4 Inhibitors
Table Global Consumption Sales by Type (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2013-2018)
Figure Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2013-2018) ($ million)
Table Global Checkpoint Inhibitors for Treating Cancer Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Checkpoint Inhibitors for Treating Cancer Value Market Share by Type (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Sale Price by Type (2013-2018)
Figure Checkpoint Inhibitors for Treating Cancer Consumed in Melanoma Treatment
Figure Global Checkpoint Inhibitors for Treating Cancer Market: Melanoma Treatment (2013-2018) (g)
Figure Global Checkpoint Inhibitors for Treating Cancer Market: Melanoma Treatment (2013-2018) ($ Millions)
Figure Global Melanoma Treatment YoY Growth ($ Millions)
Figure Checkpoint Inhibitors for Treating Cancer Consumed in Bladder Cancer Treatment
Figure Global Checkpoint Inhibitors for Treating Cancer Market: Bladder Cancer Treatment (2013-2018) (g)
Figure Global Checkpoint Inhibitors for Treating Cancer Market: Bladder Cancer Treatment (2013-2018) ($ Millions)
Figure Global Bladder Cancer Treatment YoY Growth ($ Millions)
Figure Checkpoint Inhibitors for Treating Cancer Consumed in Other
Figure Global Checkpoint Inhibitors for Treating Cancer Market: Other (2013-2018) (g)
Figure Global Checkpoint Inhibitors for Treating Cancer Market: Other (2013-2018) ($ Millions)
Figure Global Other YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2013-2018)
Figure Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Value by Application (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Value Market Share by Application (2013-2018)
Figure Global Checkpoint Inhibitors for Treating Cancer Value Market Share by Application (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2013-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Sales by Players (2016-2018) (g)
Table Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Players (2016-2018)
Figure Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Players in 2016
Figure Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Players in 2017
Table Global Checkpoint Inhibitors for Treating Cancer Revenue by Players (2016-2018) ($ Millions)
Table Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Players (2016-2018)
Figure Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Players in 2016
Figure Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Players in 2017
Table Global Checkpoint Inhibitors for Treating Cancer Sale Price by Players (2016-2018)
Figure Global Checkpoint Inhibitors for Treating Cancer Sale Price by Players in 2017
Table Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution and Sales Area by Players
Table Players Checkpoint Inhibitors for Treating Cancer Products Offered
Table Checkpoint Inhibitors for Treating Cancer Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption by Regions 2013-2018 (g)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Regions 2013-2018
Figure Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Regions 2013-2018
Table Global Checkpoint Inhibitors for Treating Cancer Value by Regions 2013-2018 ($ Millions)
Table Global Checkpoint Inhibitors for Treating Cancer Value Market Share by Regions 2013-2018
Figure Global Checkpoint Inhibitors for Treating Cancer Value Market Share by Regions 2013-2018
Figure Americas Checkpoint Inhibitors for Treating Cancer Consumption 2013-2018 (g)
Figure Americas Checkpoint Inhibitors for Treating Cancer Value 2013-2018 ($ Millions)
Figure APAC Checkpoint Inhibitors for Treating Cancer Consumption 2013-2018 (g)
Figure APAC Checkpoint Inhibitors for Treating Cancer Value 2013-2018 ($ Millions)
Figure Europe Checkpoint Inhibitors for Treating Cancer Consumption 2013-2018 (g)
Figure Europe Checkpoint Inhibitors for Treating Cancer Value 2013-2018 ($ Millions)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption 2013-2018 (g)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Value 2013-2018 ($ Millions)
Table Americas Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018) (g)
Table Americas Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries (2013-2018)
Figure Americas Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries in 2017
Table Americas Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018) ($ Millions)
Table Americas Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries (2013-2018)
Figure Americas Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries in 2017
Table Americas Checkpoint Inhibitors for Treating Cancer Consumption by Type (2013-2018) (g)
Table Americas Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2013-2018)
Figure Americas Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type in 2017
Table Americas Checkpoint Inhibitors for Treating Cancer Consumption by Application (2013-2018) (g)
Table Americas Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2013-2018)
Figure Americas Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application in 2017
Figure United States Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure United States Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Canada Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Canada Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Mexico Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Mexico Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Table APAC Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018) (g)
Table APAC Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries (2013-2018)
Figure APAC Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries in 2017
Table APAC Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018) ($ Millions)
Table APAC Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries (2013-2018)
Figure APAC Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries in 2017
Table APAC Checkpoint Inhibitors for Treating Cancer Consumption by Type (2013-2018) (g)
Table APAC Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2013-2018)
Figure APAC Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type in 2017
Table APAC Checkpoint Inhibitors for Treating Cancer Consumption by Application (2013-2018) (g)
Table APAC Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2013-2018)
Figure APAC Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application in 2017
Figure China Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure China Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Japan Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Japan Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Korea Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Korea Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Southeast Asia Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure India Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure India Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Australia Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Australia Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018) (g)
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries (2013-2018)
Figure Europe Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries in 2017
Table Europe Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018) ($ Millions)
Table Europe Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries (2013-2018)
Figure Europe Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries in 2017
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption by Type (2013-2018) (g)
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2013-2018)
Figure Europe Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type in 2017
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption by Application (2013-2018) (g)
Table Europe Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2013-2018)
Figure Europe Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application in 2017
Figure Germany Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Germany Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure France Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure France Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure UK Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure UK Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Italy Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Italy Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Russia Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Russia Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Spain Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Spain Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Countries (2013-2018) (g)
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Countries in 2017
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Value Market Share by Countries in 2017
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Type (2013-2018) (g)
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Type in 2017
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption by Application (2013-2018) (g)
Table Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application in 2017
Figure Egypt Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Egypt Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure South Africa Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure South Africa Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Israel Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Israel Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure Turkey Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure Turkey Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Checkpoint Inhibitors for Treating Cancer Consumption Growth 2013-2018 (g)
Figure GCC Countries Checkpoint Inhibitors for Treating Cancer Value Growth 2013-2018 ($ Millions)
Table Checkpoint Inhibitors for Treating Cancer Distributors List
Table Checkpoint Inhibitors for Treating Cancer Customer List
Figure Global Checkpoint Inhibitors for Treating Cancer Consumption Growth Rate Forecast (2018-2023) (g)
Figure Global Checkpoint Inhibitors for Treating Cancer Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Countries (2018-2023) (g)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Market Forecast by Regions
Table Global Checkpoint Inhibitors for Treating Cancer Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Checkpoint Inhibitors for Treating Cancer Value Market Share Forecast by Regions
Figure Americas Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Americas Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure APAC Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure APAC Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Europe Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Europe Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Middle East & Africa Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure United States Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure United States Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Canada Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Canada Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Mexico Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Mexico Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Brazil Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Brazil Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure China Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure China Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Japan Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Japan Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Korea Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Korea Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Southeast Asia Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Southeast Asia Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure India Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure India Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Australia Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Australia Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Germany Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Germany Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure France Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure France Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure UK Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure UK Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Italy Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Italy Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Russia Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Russia Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Spain Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Spain Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Egypt Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Egypt Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure South Africa Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure South Africa Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Israel Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Israel Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure Turkey Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure Turkey Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Figure GCC Countries Checkpoint Inhibitors for Treating Cancer Consumption 2018-2023 (g)
Figure GCC Countries Checkpoint Inhibitors for Treating Cancer Value 2018-2023 ($ Millions)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Type (2018-2023) (g)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share Forecast by Type (2018-2023)
Table Global Checkpoint Inhibitors for Treating Cancer Value Forecast by Type (2018-2023) ($ Millions)
Table Global Checkpoint Inhibitors for Treating Cancer Value Market Share Forecast by Type (2018-2023)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Application (2018-2023) (g)
Table Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share Forecast by Application (2018-2023)
Table Global Checkpoint Inhibitors for Treating Cancer Value Forecast by Application (2018-2023) ($ Millions)
Table Global Checkpoint Inhibitors for Treating Cancer Value Market Share Forecast by Application (2018-2023)
Table Bristol-Myers Squibb(BMS) Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Market Share (2016-2018)
Table Merck Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Merck Checkpoint Inhibitors for Treating Cancer Market Share (2016-2018)
Table Roche Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Roche Checkpoint Inhibitors for Treating Cancer Market Share (2016-2018)
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
